{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:26:59Z","timestamp":1794324419478,"version":"4.9.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001803","name":"Charles Darwin University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001803","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40261-022-01204-z","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T17:02:46Z","timestamp":1665421366000},"page":"23-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8228-1536","authenticated-orcid":false,"given":"Amy","family":"Legg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Meagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Cass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.","family":"Scheetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Y. C.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"issue":"10","key":"1204_CR1","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1097\/01.CCM.0000239121.09533.09","volume":"34","author":"AF Shorr","year":"2006","unstructured":"Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large US database. Crit Care Med. 2006;34(10):2588\u201395. https:\/\/doi.org\/10.1097\/01.CCM.0000239121.09533.09.","journal-title":"Crit Care Med"},{"issue":"3","key":"1204_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S1473-3099(10)70285-1","volume":"11","author":"GE Thwaites","year":"2011","unstructured":"Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Torok ME, et al. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. 2011;11(3):208\u201322. https:\/\/doi.org\/10.1016\/S1473-3099(10)70285-1.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1204_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/CMR.05022-11","volume":"25","author":"SJ van Hal","year":"2012","unstructured":"van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012;25(2):362\u201386. https:\/\/doi.org\/10.1128\/CMR.05022-11.","journal-title":"Clin Microbiol Rev"},{"key":"1204_CR4","volume-title":"AURA 2019: third Australian report on antimicrobial use and resistance in human health","author":"Australian Commission on Safety and Quality in Health Care (ACSQHC)","year":"2019","unstructured":"Australian Commission on Safety and Quality in Health Care (ACSQHC). AURA 2019: third Australian report on antimicrobial use and resistance in human health. Sydney: ACSQHC; 2019."},{"issue":"9","key":"1204_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","volume":"68","author":"AP Kourtis","year":"2019","unstructured":"Kourtis AP, Hatfield K, Baggs J, Mu Y, See I, Epson E, et al. Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections: United States. MMWR Morb Mortal Wkly Rep. 2019;68(9):214\u20139. https:\/\/doi.org\/10.15585\/mmwr.mm6809e1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"1204_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SY Tong","year":"2015","unstructured":"Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603\u201361. https:\/\/doi.org\/10.1128\/CMR.00134-14.","journal-title":"Clin Microbiol Rev"},{"key":"1204_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.02429-21","author":"M Verway","year":"2022","unstructured":"Verway M, Brown KA, Marchand-Austin A, Diong C, Lee S, Langford B, et al. Prevalence and mortality associated with bloodstream organisms: a population-wide retrospective cohort study. J Clin Microbiol. 2022. https:\/\/doi.org\/10.1128\/jcm.02429-21.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"1204_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jhin.2012.12.008","volume":"83","author":"EJ Joo","year":"2013","unstructured":"Joo EJ, Peck KR, Ha YE, Kim YS, Song YG, Lee SS, et al. Impact of acute kidney injury on mortality and medical costs in patients with meticillin-resistant Staphylococcus aureus bacteraemia: a retrospective, multicentre observational study. J Hosp Infect. 2013;83(4):300\u20136. https:\/\/doi.org\/10.1016\/j.jhin.2012.12.008.","journal-title":"J Hosp Infect"},{"issue":"6","key":"1204_CR9","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s40620-021-00970-x","volume":"34","author":"RA Prabhu","year":"2021","unstructured":"Prabhu RA, Shaw T, Rao IR, Kalwaje Eshwara V, Nagaraju SP, Shenoy SV, et al. Acute kidney injury and its outcomes in melioidosis. J Nephrol. 2021;34(6):1941\u20138. https:\/\/doi.org\/10.1007\/s40620-021-00970-x.","journal-title":"J Nephrol"},{"issue":"4","key":"1204_CR10","first-page":"380","volume":"27","author":"M Papadimitriou-Olivgeris","year":"2019","unstructured":"Papadimitriou-Olivgeris M, Assimakopoulos SF, Kolonitsiou F, Solomou A, Vamvakopoulou S, Spyropoulou A, et al. Risk factors for acute kidney injury in critically ill patients with bacteraemia by carbapenem non-susceptible Gram negative bacteria. Infez Med. 2019;27(4):380\u201392.","journal-title":"Infez Med"},{"key":"1204_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jcpt.12203","volume":"12","author":"RG Hall 2nd","year":"2012","unstructured":"Hall RG 2nd, Giuliano CA, Haase KK, Hazlewood KA, Frei CR, Forcade NA, et al. Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Infect Dis. 2012;12:104. https:\/\/doi.org\/10.1111\/jcpt.12203.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"1204_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2215\/CJN.10410919","volume":"15","author":"RA Noble","year":"2020","unstructured":"Noble RA, Lucas BJ, Selby NM. Long-term outcomes in patients with acute kidney injury. Clin J Am Soc Nephrol. 2020;15(3):423\u20139. https:\/\/doi.org\/10.2215\/CJN.10410919.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"19","key":"1204_CR13","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1001\/archinte.162.19.2229","volume":"162","author":"SI Blot","year":"2002","unstructured":"Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med. 2002;162(19):2229\u201335. https:\/\/doi.org\/10.1001\/archinte.162.19.2229.","journal-title":"Arch Intern Med"},{"key":"1204_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12941-016-0122-8","volume":"15","author":"M Yilmaz","year":"2016","unstructured":"Yilmaz M, Elaldi N, Balkan II, Arslan F, Batirel AA, Bakici MZ, et al. Mortality predictors of Staphylococcus aureus bacteremia: a prospective multicenter study. Ann Clin Microbiol Antimicrob. 2016;15:7. https:\/\/doi.org\/10.1186\/s12941-016-0122-8.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"2","key":"1204_CR15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","volume":"57","author":"SJ van Hal","year":"2013","unstructured":"van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734\u201344. https:\/\/doi.org\/10.1128\/AAC.01568-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1204_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jama.2020.0103","volume":"323","author":"SYC Tong","year":"2020","unstructured":"Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527\u201337. https:\/\/doi.org\/10.1001\/jama.2020.0103.","journal-title":"JAMA"},{"issue":"2","key":"1204_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/cid\/civ808","volume":"62","author":"JS Davis","year":"2016","unstructured":"Davis JS, Sud A, O\u2019Sullivan MVN, Robinson JO, Ferguson PE, Foo H, et al. Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62(2):173\u201380. https:\/\/doi.org\/10.1093\/cid\/civ808.","journal-title":"Clin Infect Dis"},{"key":"1204_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/cid\/civ808","volume":"17","author":"SY Tong","year":"2016","unstructured":"Tong SY, Nelson J, Paterson DL, Fowler VG Jr, Howden BP, Cheng AC, et al. CAMERA2\u2014combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials. 2016;17:170. https:\/\/doi.org\/10.1093\/cid\/civ808.","journal-title":"Trials"},{"issue":"11","key":"1204_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245\u201351. https:\/\/doi.org\/10.1016\/0895-4356(94)90129-5.","journal-title":"J Clin Epidemiol"},{"key":"1204_CR20","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2017.14482","volume":"147","author":"JA Roth","year":"2017","unstructured":"Roth JA, Tschudin-Sutter S, Dangel M, Frei R, Battegay M, Widmer AF. Value of the Pitt bacteraemia score to predict short-term mortality in Staphylococcus aureus bloodstream infection: a validation study. Swiss Med Wkly. 2017;147: w14482. https:\/\/doi.org\/10.4414\/smw.2017.14482.","journal-title":"Swiss Med Wkly"},{"issue":"7","key":"1204_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707\u201310. https:\/\/doi.org\/10.1007\/BF01709751.","journal-title":"Intensive Care Med"},{"issue":"12","key":"1204_CR22","doi-asserted-by":"publisher","first-page":"ofaa538","DOI":"10.1093\/ofid\/ofaa538","volume":"7","author":"J Liu","year":"2020","unstructured":"Liu J, Tong SYC, Davis JS, Rhodes NJ, Scheetz MH, Group CS. Vancomycin exposure and acute kidney injury outcome: a snapshot from the CAMERA2 Study. Open Forum Infect Dis. 2020;7(12):ofaa538. https:\/\/doi.org\/10.1093\/ofid\/ofaa538.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"1204_CR23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc2872","volume":"8","author":"R Bellomo","year":"2004","unstructured":"Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative Workgroup. Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):204\u201312. https:\/\/doi.org\/10.1186\/cc2872.","journal-title":"Crit Care"},{"key":"1204_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1\u2013138.","journal-title":"Kidney Int Suppl"},{"key":"1204_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/9781118548387","volume-title":"Applied logistic regression","author":"DW Hosmer","year":"2013","unstructured":"Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. Hoboken: Wiley; 2013.","edition":"3"},{"issue":"6","key":"1204_CR26","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/ajhp\/zxaa036","volume":"71","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71(6):1361\u20134. https:\/\/doi.org\/10.1093\/ajhp\/zxaa036.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1204_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204. https:\/\/doi.org\/10.1186\/cc11454.","journal-title":"Crit Care"},{"issue":"9","key":"1204_CR28","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1097\/CCM.0b013e3181a5906f","volume":"37","author":"CV Thakar","year":"2009","unstructured":"Thakar CV, Christianson A, Freyberg R, Almenoff P, Render ML. Incidence and outcomes of acute kidney injury in intensive care units: a Veterans Administration study. Crit Care Med. 2009;37(9):2552\u20138. https:\/\/doi.org\/10.1097\/CCM.0b013e3181a5906f.","journal-title":"Crit Care Med"},{"issue":"6","key":"1204_CR29","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1097\/01.asn.0000130340.93930.dd","volume":"15","author":"A Lassnigg","year":"2004","unstructured":"Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol. 2004;15(6):1597\u2013605. https:\/\/doi.org\/10.1097\/01.asn.0000130340.93930.dd.","journal-title":"J Am Soc Nephrol"},{"key":"1204_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxab247","author":"KC Yu","year":"2021","unstructured":"Yu KC, Yamaga C, Vankeepuram L, Tabak YP. Relationships between creatinine increase and mortality rates in patients given vancomycin in 76 hospitals: the increasing role of infectious disease pharmacists. Am J Health Syst Pharm. 2021. https:\/\/doi.org\/10.1093\/ajhp\/zxab247.","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"1204_CR31","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1128\/AAC.00173-11","volume":"55","author":"E Minejima","year":"2011","unstructured":"Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011;55(7):3278\u201383. https:\/\/doi.org\/10.1128\/AAC.00173-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1204_CR32","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","volume":"68","author":"S Elyasi","year":"2012","unstructured":"Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations: a literature review. Eur J Clin Pharmacol. 2012;68(9):1243\u201355. https:\/\/doi.org\/10.1007\/s00228-012-1259-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1204_CR33","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/cid\/ciz051","volume":"69","author":"DM Aljefri","year":"2019","unstructured":"Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH. Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin Infect Dis. 2019;69(11):1881\u20137. https:\/\/doi.org\/10.1093\/cid\/ciz051.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1204_CR34","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1093\/jac\/dkz167","volume":"74","author":"SN Avedissian","year":"2019","unstructured":"Avedissian SN, Pais GM, O\u2019Donnell JN, Lodise TP, Liu J, Prozialeck WC, et al. Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. J Antimicrob Chemother. 2019;74(8):2326\u201334. https:\/\/doi.org\/10.1093\/jac\/dkz167.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1204_CR35","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1128\/AAC.00591-16","volume":"60","author":"NJ Rhodes","year":"2016","unstructured":"Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O\u2019Donnell JN, Pais G, et al. Evaluation of vancomycin exposures associated with elevations in novel urinary biomarkers of acute kidney injury in vancomycin-treated rats. Antimicrob Agents Chemother. 2016;60(10):5742\u201351. https:\/\/doi.org\/10.1128\/AAC.00591-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1204_CR36","first-page":"1009","volume":"37","author":"B Xu","year":"2008","unstructured":"Xu B, Murray M. Flucloxacillin induced acute renal failure. Aust Fam Physician. 2008;37(12):1009\u201311.","journal-title":"Aust Fam Physician"},{"issue":"4","key":"1204_CR37","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/ndt\/10.4.579","volume":"10","author":"SJ Bakker","year":"1995","unstructured":"Bakker SJ, Luik AJ, Leunissen KM. Flucloxacillin-induced acute interstitial nephritis. Nephrol Dial Transplant. 1995;10(4):579.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1204_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.7326\/0003-4819-93-5-735","volume":"93","author":"AL Linton","year":"1980","unstructured":"Linton AL, Clark WF, Driedger AA, Turnbull DI, Lindsay RM. Acute interstitial nephritis due to drugs: review of the literature with a report of nine cases. Ann Intern Med. 1980;93(5):735\u201341. https:\/\/doi.org\/10.7326\/0003-4819-93-5-735.","journal-title":"Ann Intern Med"},{"issue":"12","key":"1204_CR39","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.2215\/CJN.07630717","volume":"12","author":"DG Moledina","year":"2017","unstructured":"Moledina DG, Perazella MA. Drug-induced acute interstitialnNephritis. Clin J Am Soc Nephrol. 2017;12(12):2046\u20139. https:\/\/doi.org\/10.2215\/CJN.07630717.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1204_CR40","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.cmi.2020.03.019","volume":"26","author":"I Bellos","year":"2020","unstructured":"Bellos I, Karageorgiou V, Pergialiotis V, Perrea DN. Acute kidney injury following the concurrent administration of antipseudomonal beta-lactams and vancomycin: a network meta-analysis. Clin Microbiol Infect. 2020;26(6):696\u2013705. https:\/\/doi.org\/10.1016\/j.cmi.2020.03.019.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1204_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","volume":"46","author":"MK Luther","year":"2018","unstructured":"Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46(1):12\u201320. https:\/\/doi.org\/10.1097\/CCM.0000000000002769.","journal-title":"Crit Care Med"},{"issue":"7","key":"1204_CR42","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/1060028018757497","volume":"52","author":"BP Mullins","year":"2018","unstructured":"Mullins BP, Kramer CJ, Bartel BJ, Catlin JS, Gilder RE. Comparison of the nephrotoxicity of vancomycin in combination with cefepime, meropenem, or piperacillin\/tazobactam: a prospective, multicenter study. Ann Pharmacother. 2018;52(7):639\u201344. https:\/\/doi.org\/10.1177\/1060028018757497.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"1204_CR43","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1093\/cid\/cix675","volume":"65","author":"RR Watkins","year":"2017","unstructured":"Watkins RR, Deresinski S. Increasing evidence of the nephrotoxicity of piperacillin\/tazobactam and vancomycin combination therapy: what is the clinician to do? Clin Infect Dis. 2017;65(12):2137\u201343. https:\/\/doi.org\/10.1093\/cid\/cix675.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1204_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000513742","volume":"52","author":"M Blair","year":"2021","unstructured":"Blair M, Cote JM, Cotter A, Lynch B, Redahan L, Murray PT. Nephrotoxicity from vancomycin combined with piperacillin-tazobactam: a comprehensive review. Am J Nephrol. 2021;52(2):85\u201397. https:\/\/doi.org\/10.1159\/000513742.","journal-title":"Am J Nephrol"},{"issue":"2","key":"1204_CR45","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/cid\/ciz1189","volume":"71","author":"SN Avedissian","year":"2020","unstructured":"Avedissian SN, Pais GM, Liu J, Rhodes NJ, Scheetz MH. Piperacillin-tazobactam added to vancomycin increases risk for acute kidney injury: fact or fiction? Clin Infect Dis. 2020;71(2):426\u201332. https:\/\/doi.org\/10.1093\/cid\/ciz1189.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1204_CR46","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1093\/cid\/ciab452","volume":"73","author":"W Rose","year":"2021","unstructured":"Rose W, Fantl M, Geriak M, Nizet V, Sakoulas G. Current paradigms of combination therapy in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: does it work, which combination, and for which patients? Clin Infect Dis. 2021;73(12):2353\u201360. https:\/\/doi.org\/10.1093\/cid\/ciab452.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1204_CR47","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1124\/dmd.112.049569","volume":"41","author":"AT Wolman","year":"2013","unstructured":"Wolman AT, Gionfriddo MR, Heindel GA, Mukhija P, Witkowski S, Bommareddy A, et al. Organic anion transporter 3 interacts selectively with lipophilic beta-lactam antibiotics. Drug Metab Dispos. 2013;41(4):791\u2013800. https:\/\/doi.org\/10.1124\/dmd.112.049569.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1204_CR48","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/jac\/dks510","volume":"68","author":"V Raverdy","year":"2013","unstructured":"Raverdy V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother. 2013;68(5):1179\u201382. https:\/\/doi.org\/10.1093\/jac\/dks510.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1204_CR49","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.ekir.2020.04.008","volume":"5","author":"B Lazarus","year":"2020","unstructured":"Lazarus B, Davies MRP, Trubiano JA, Pellicano R. Time to acute kidney injury in beta-lactam-induced acute interstitial nephritis. Kidney Int Rep. 2020;5(7):1068\u201370. https:\/\/doi.org\/10.1016\/j.ekir.2020.04.008.","journal-title":"Kidney Int Rep."},{"issue":"4","key":"1204_CR50","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/ckj\/sfaa059","volume":"14","author":"J Graham","year":"2021","unstructured":"Graham J, Borthwick E, Hill C, Blaney J, Gallagher N, Armstrong L, et al. Acute kidney injury following prophylactic flucloxacillin and gentamicin in primary hip and knee arthroplasty. Clin Kidney J. 2021;14(4):1114\u20139. https:\/\/doi.org\/10.1093\/ckj\/sfaa059.","journal-title":"Clin Kidney J"},{"issue":"3","key":"1204_CR51","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/ndt\/gfs458","volume":"28","author":"SR Challagundla","year":"2013","unstructured":"Challagundla SR, Knox D, Hawkins A, Hamilton D, Flynn RWV, Robertson S, et al. Renal impairment after high-dose flucloxacillin and single-dose gentamicin prophylaxis in patients undergoing elective hip and knee replacement. Nephrol Dial Transplant. 2013;28(3):612\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfs458.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1204_CR52","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/jac\/dkt402","volume":"69","author":"K Norton","year":"2014","unstructured":"Norton K, Ingram PR, Heath CH, Manning L. Risk factors for nephrotoxicity in patients receiving outpatient continuous infusions of vancomycin in an Australian tertiary hospital. J Antimicrob Chemother. 2014;69(3):805\u20138. https:\/\/doi.org\/10.1093\/jac\/dkt402.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1204_CR53","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/cid\/ciz460","volume":"70","author":"TP Lodise","year":"2020","unstructured":"Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, et al. The emperor\u2019s new clothes: PRospective Observational evaluation of the association between initial VancomycIn exposure and failure rates among ADult HospitalizEd patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE). Clin Infect Dis. 2020;70(8):1536\u201345. https:\/\/doi.org\/10.1093\/cid\/ciz460.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1204_CR54","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01060-21","volume":"65","author":"MH Scheetz","year":"2021","unstructured":"Scheetz MH, Pais GM, Lodise TP, Tong SYC, Davis JS, O\u2019Donnell JN, et al. Of rats and men: a translational model to understand vancomycin pharmacokinetic\/toxicodynamic relationships. Antimicrob Agents Chemother. 2021;65(10): e0106021. https:\/\/doi.org\/10.1128\/AAC.01060-21.","journal-title":"Antimicrob Agents Chemother"}],"updated-by":[{"DOI":"10.1007\/s40261-022-01224-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01204-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01204-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01204-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T10:10:07Z","timestamp":1673431807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01204-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1204"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01204-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40261-022-01224-9","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"assertion":[{"value":"13 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-022-01224-9","URL":"https:\/\/doi.org\/10.1007\/s40261-022-01224-9","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The CAMERA2 trial was supported by Australian National Health & Medical Research Council Career Development Fellowships for Steven Y. C. Tong (1145033) and Joshua S. Davis (1160331).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marc H. Scheetz has ongoing research contracts with Nevakar and SuperTrans Medical as well as having filed patent US10688195B2. He is supported in part by the National Institute of Allergy and Infectious Diseases under award number R21-AI149026. Jason A. Roberts acknowledge funding from the Australian National Health and Medical Research Council for a Centre of Research Excellence (APP2007007) and an Investigator Grant (APP2009736) as well as an Advancing Queensland Clinical Fellowship. Amy Legg, Niamh Meagher, Sandra A. Johnson, Matthew A. Roberts, Alan Cass, Jane Davies, Joshua S. Davis and Steven Y.C. Tong have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in this study were in accordance with the 1964 Declaration of Helsinki (and its amendments). Institutional ethics approval was obtained at each site as amendments to the CAMERA2 trial approval (principal site Hunter New England 2019\/ETH00841).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from each participant or surrogate decision maker for the CAMERA2 trial.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Deidentified data can be made available based on a reasonable request to the authors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not available.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualisation ST, JoD, ST; statistical analysis: NM; draft manuscript: AL JoD, ST, manuscript review and advice: all authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}